Fort Washington Investment Advisors Inc. OH Sells 213,366 Shares of Johnson & Johnson (NYSE:JNJ)

Fort Washington Investment Advisors Inc. OH trimmed its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 12.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,489,208 shares of the company's stock after selling 213,366 shares during the quarter. Johnson & Johnson accounts for 1.5% of Fort Washington Investment Advisors Inc. OH's portfolio, making the stock its 12th largest holding. Fort Washington Investment Advisors Inc. OH owned approximately 0.06% of Johnson & Johnson worth $246,970,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the 4th quarter valued at about $29,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $38,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $0.24 during mid-day trading on Friday, hitting $156.90. The stock had a trading volume of 6,587,488 shares, compared to its average volume of 7,947,693. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company's 50 day simple moving average is $153.69 and its 200 day simple moving average is $153.71. The stock has a market cap of $377.52 billion, a price-to-earnings ratio of 23.59, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson's payout ratio is 57.84%.

Analyst Ratings Changes

A number of brokerages recently commented on JNJ. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Barclays reduced their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.